Rapid elimination of cervical cancer while maintaining the harms and benefits ratio of cervical cancer screening: a modelling study

[1] Hall MT(2019)The projected timeframe until cervical cancer elimination in Australia: a modelling study Lancet Public Health 4 e19-e27

[2] Simms KT(2020)Projected time to elimination of cervical cancer in the USA: a comparative modelling study Lancet Public Health 5 e213-e222

[3] Lew JB(2017)Quantifying Overdiagnosis in Cancer Screening: A Systematic Review to Evaluate the Methodology J Natl Cancer Inst 109 1-130

[4] Smith MA(1997)Non-progression of cervical intraepithelial neoplasia estimated from population-screening data Br J Cancer 75 124-148

[5] Brotherton JM(2016)Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis BMJ 354 142-1765

[6] Saville M(2014)How distressing is referral to colposcopy in cervical cancer screening?: a prospective quality of life study Gynecol Oncol 132 1757-1652

[7] Burger EA(2004)Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial Lancet 364 1643-515

[8] Smith MA(2020)Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial Lancet Oncol 21 505-966

[9] Killen J(2011)Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence Epidemiology 22 958-346

[10] Sy S(2014)Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study Lancet Infect Dis 14 321-582

[1] Hall MT(2019)The projected timeframe until cervical cancer elimination in Australia: a modelling study Lancet Public Health 4 e19-e27

[2] Simms KT(2020)Projected time to elimination of cervical cancer in the USA: a comparative modelling study Lancet Public Health 5 e213-e222

[3] Lew JB(2017)Quantifying Overdiagnosis in Cancer Screening: A Systematic Review to Evaluate the Methodology J Natl Cancer Inst 109 1-130

[4] Smith MA(1997)Non-progression of cervical intraepithelial neoplasia estimated from population-screening data Br J Cancer 75 124-148

[5] Brotherton JM(2016)Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis BMJ 354 142-1765

[6] Saville M(2014)How distressing is referral to colposcopy in cervical cancer screening?: a prospective quality of life study Gynecol Oncol 132 1757-1652

[7] Burger EA(2004)Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial Lancet 364 1643-515

[8] Smith MA(2020)Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial Lancet Oncol 21 505-966

[9] Killen J(2011)Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence Epidemiology 22 958-346

[10] Sy S(2014)Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study Lancet Infect Dis 14 321-582